ACER

Acer Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with significant unmet medical needs.

Headquartered in Newton, Massachusetts, Acer’s pipeline has included clinical-stage candidates like OLPRUVA™ (sodium phenylbutyrate) for urea cycle disorders, EDSIVO™ (celiprolol) for vascular Ehlers-Danlos syndrome, and others targeting inborn errors of metabolism and vasomotor symptoms.

In November 2023, Acer was acquired by Zevra Therapeutics, bringing its rare-disease assets into Zevra’s broader portfolio.